News

Eris Lifesciences Limited announced that Krishnakumar Vaidyanathan has resigned from his position as Executive Director & Chief Operating Officer (COO), effective September 30, 2026, to pursue professional opportunities outside the organization.

Eris Lifesciences Limited informed the Bombay Stock Exchange and National Stock Exchange of India that its board of directors approved the re-appointment of Mr. Sujesh Vasudevan as an Independent Director for a period of 5 years, commencing July 25, 2027, and up to July 24, 2032, and convened the 20th Annual General Meeting of its members for September 25, 2026.

Eris Lifesciences has drawn down a working capital term loan amounting to Rs 64.40 crore from Axis Bank to meet other short-term liabilities. The aggregate debt level of the company would, therefore, remain unchanged.

Net profit of ERIS Lifesciences rose 20.68% to Rs 142.39 crore in the quarter ended June 2026 as against Rs 117.99 crore during the previous quarter ended June 2025. Sales rose 12.63% to Rs 869.03 crore in the quarter ended June 2026 as against Rs 771.56 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales869.03771.56 13 OPM %34.0435.86 - PBDT251.56231.61 9 PBT179.49161.10 11 NP142.39117.99 21 Powered by Capital Market - Live News

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 29 July 2026.